# Momotaro-Gene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/momotaro-gene

- Industry: Biotechnology
- Headquarters: Okayama-shi, Japan
- Website: www.mt-gene.com
- Total disclosed funding: $15M
- Latest round: Series B (Mar 15, 2019)
- Investors on record: 6

## About

Based in Okayama-shi, Japan, Momotaro-Gene Inc. is engaged in developing innovative cancer therapies that utilize genetic and pharmaceutical combinations to target various tumors effectively.Momotaro-Gene Inc. focuses on creating advanced cancer treatment solutions. Founded in 2007, the company has undergone strategic developments, raising JPY 499.920 mn during its SERIES D funding round in April 2023, with investor Adreic Therapeutics Inc. Momotaro-Gene has successfully managed 3 deals to date and boasts a current valuation of JPY 2,415.529 mn.Momotaro-Gene Inc. specializes in developing innovative cancer therapies that leverage genetic and pharmaceutical combinations to target various tumors. Their primary offerings include a patented combination therapy utilizing the REIC/Dkk-3 gene and checkpoint inhibitors, aimed at enhancing the effectiveness of existing cancer treatments. Additionally, the company is advancing a method for treating liver cancer that combines REIC/Dkk-3 with antitumor agents. These therapies are undergoing clinical trials, including phase I/IIa studies conducted at Okayama University Hospital, specifically targeting malignant gliomas. Momotaro-Gene's products are primarily intended for use in the Japanese healthcare market, with potential implications for broader international markets as the development progresses.Momotaro-Gene Inc. generates revenue through strategic partnerships and collaborations within the pharmaceutical industry, particularly focusing on the oncology sector. The company's business model involves agreements with healthcare institutions and pharmaceutical companies for the co-development and commercialization of their therapeutic solutions. Transactions occur through licensing arrangements, where clinical trial results may lead to further investment and support from partners. Revenue is derived from milestones achieved during the drug development process and potential royalties on future sales of successfully marketed therapies. Details regarding specific pricing structures or revenue figures have not been disclosed.In April 2023, Momotaro-Gene Inc. raised JPY 500 million in SERIES D funding, which will enable the company to strengthen its financial base. The firm is focused on advancing its innovative cancer therapies, with plans to expand its reach into new geographical markets beyond Japan as development progresses. The funding is expected to support these initiatives, allowing for enhanced research and potential product launches in the coming years.

## Funding rounds

- Series B, Mar 15, 2019, $4.7M — KYORIN Pharmaceutical, SMBC Venture Capital, Nissay Capital, Hiroshima Venture Capital, EPS Holdings
- Series A, Mar 15, 2017, $10M — Daiwa Corporate Investment, KYORIN Pharmaceutical, Nissay Capital

## Investors

- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series A
- KYORIN Pharmaceutical — Series A, Series B
- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series A, Series B
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series B
- Hiroshima Venture Capital (https://capitalatlas.ai/funds/hiroshima-venture-capital) — Series B
- EPS Holdings — Series B